ENDRA Life Sciences Inc. (NDRA) Stock Forecast
NDRA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $25.00 average of analyst targets
- Upside to target
- +427.4% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.84
- 52-week range
- $3.26 – $6.70
NDRA analyst ratings
1 analystsNumber of analysts at each rating.
NDRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NDRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.84 | −$0.84 | −$0.84 | −$2.10 | +60.0% | 1 |
| Current fiscal year (2026) | −$3.54 | −$3.54 | −$3.54 | −$7.67 | +53.8% | 1 |
| Next fiscal year (2027) | −$3.04 | −$3.04 | −$3.04 | −$3.54 | +14.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NDRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $200,000 | $200,000 | $200,000 | 0.0% | 1 |
NDRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NDRA revenue: reported and forecast
NDRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.14 | −$1.14 | −$1.14 | −$1.14 | −$0.84 | −26.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$4.62 | −$4.62 | −$4.65 | −$4.65 | −$3.54 | −23.4% | 1 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | −$4.00 | −$4.00 | −$3.04 | — | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NDRA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NDRA beat in 9 of 12.
What analysts expect from NDRA
1 analysts cover ENDRA Life Sciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.00, 427.4% above the latest close of $4.74. Analysts expect earnings of −$3.54 per share for 2026, +53.8% from a year earlier. For 2027 the average estimate is −$3.04 per share on revenue of $0.2 million. ENDRA Life Sciences beat the EPS estimate in 9 of the last 12 quarters.
Related: NDRA income statement, NDRA key metrics, NDRA chart. See the NDRA stock overview for the latest quote and news.
NDRA forecast FAQ
What is ENDRA Life Sciences's price target?
The average analyst price target for ENDRA Life Sciences is $25.00, 427.4% above the latest close of $4.74.
Is ENDRA Life Sciences a buy, hold or sell?
Of 1 analysts covering ENDRA Life Sciences, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ENDRA Life Sciences's EPS forecast?
Analysts forecast −$3.54 per share for 2026 (range −$3.54 to −$3.54); for 2027 the estimate is −$3.04.
When does ENDRA Life Sciences report earnings?
ENDRA Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.84.
Does ENDRA Life Sciences usually beat earnings estimates?
ENDRA Life Sciences reported EPS at or above the analyst estimate in 9 of the last 12 quarters.